-0.000116511847136454 0.000715715632409768 0.0015328117032369 0.00194135973865046 0.00147228606836074 0.0041959396377845 0.00313674102745297 0.00109400085038515
Sign Up Today X
Thanks for submitting the form.
Stockreport

Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72% [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Reach USD 21.92 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Sorrento Therapeutics, Inc., Novartis AG, GSK plc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, JW Therapeutics (Shanghai) Co., Ltd., Sangamo Therapeutics, bluebird bio, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., and Other key vendors. New York, United States, April 18, 2024 (GLOBE NEWSWIRE) -- The Global CAR T-Cell Therapy Market Size is to Grow from USD 4.29 Billion in 2023 to USD 21.92 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 17.72% during the projected period. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4117 Chimeric antigen receptor (CAR) T-cell therapy is the use of T cells, which are immune cells, that have been genetically modified in a lab to increase their ability to recognize and eliminate cancer cells. For some tumors, CAR T-cell therapy can be extremely effective w [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72% [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Reach USD 21.92 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Sorrento Therapeutics, Inc., Novartis AG, GSK plc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, JW Therapeutics (Shanghai) Co., Ltd., Sangamo Therapeutics, bluebird bio, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., and Other key vendors. New York, United States, April 18, 2024 (GLOBE NEWSWIRE) -- The Global CAR T-Cell Therapy Market Size is to Grow from USD 4.29 Billion in 2023 to USD 21.92 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 17.72% during the projected period. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4117 Chimeric antigen receptor (CAR) T-cell therapy is the use of T cells, which are immune cells, that have been genetically modified in a lab to increase their ability to recognize and eliminate cancer cells. For some tumors, CAR T-cell therapy can be extremely effective w [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS